Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Nutr Hosp ; 35(6): 1394-1400, 2018 Dec 03.
Artigo em Inglês | MEDLINE | ID: mdl-30525855

RESUMO

BACKGROUND: patients with cervical cancer (CC) receiving chemotherapy and radiotherapy have several gastrointestinal adverse effects. OBJECTIVE: to evaluate the effect of dietary symbiotic supplementation on fecal calprotectin (FCP), bacterial DNA levels, and gastrointestinal adverse effects in patients with CC. METHODS: clinical, controlled, randomized, double-blind trial. Patients consumed symbiotics or placebo three times a day for seven weeks. FCP was assessed by Elisa method. DNA from probiotic and pathogenic bacteria were determined by quantitative real-time polymerase chain reaction. Diarrheal evacuations were evaluated with the Bristol stool form scale and nausea and vomiting were measured using the scale of the National Institute of Cancerology of the United States. RESULTS: after a seven-week treatment, FCP concentration was lower in the symbiotic group compared to the control group (p < 0.001). Stool consistency in the placebo and symbiotic groups was similar at baseline. A significant improvement in stool consistency was obtained in both groups at the end of the intervention (p < 0.001). The concentrations and total proportions of the probiotic and pathogenic bacteria were similar in both groups. Nausea significantly diminished in both groups (p < 0.001) at the end of the trial. Furthermore, the symbiotic group had a statistically significant decrease in the frequency and intensity of vomiting when compared to the control group (p < 0.001). CONCLUSIONS: the symbiotic treatment decreases significantly the FCP levels and the frequency and intensity of vomiting in patients with CC.


Assuntos
Fezes/química , Fezes/microbiologia , Complexo Antígeno L1 Leucocitário/análise , Prebióticos/administração & dosagem , Probióticos/administração & dosagem , Neoplasias do Colo do Útero/terapia , Adulto , Antineoplásicos/efeitos adversos , Bifidobacterium/genética , DNA Bacteriano/análise , Suplementos Nutricionais , Método Duplo-Cego , Escherichia coli/genética , Feminino , Gastroenteropatias/etiologia , Gastroenteropatias/prevenção & controle , Humanos , Inflamação/etiologia , Inflamação/prevenção & controle , Lactobacillales/genética , Pessoa de Meia-Idade , Placebos , Radioterapia/efeitos adversos , Salmonella/genética , Neoplasias do Colo do Útero/complicações
2.
Nutr. hosp ; 35(6): 1394-1400, nov.-dic. 2018. tab, graf
Artigo em Inglês | IBECS | ID: ibc-181482

RESUMO

Background: patients with cervical cancer (CC) receiving chemotherapy and radiotherapy have several gastrointestinal adverse effects. Objective: to evaluate the effect of dietary symbiotic supplementation on fecal calprotectin (FCP), bacterial DNA levels, and gastrointestinal adverse effects in patients with CC. Methods: clinical, controlled, randomized, double-blind trial. Patients consumed symbiotics or placebo three times a day for seven weeks. FCP was assessed by Elisa method. DNA from probiotic and pathogenic bacteria were determined by quantitative real-time polymerase chain reaction. Diarrheal evacuations were evaluated with the Bristol stool form scale and nausea and vomiting were measured using the scale of the National Institute of Cancerology of the United States. Results: after a seven-week treatment, FCP concentration was lower in the symbiotic group compared to the control group (p < 0.001). Stool consistency in the placebo and symbiotic groups was similar at baseline. A significant improvement in stool consistency was obtained in both groups at the end of the intervention (p < 0.001). The concentrations and total proportions of the probiotic and pathogenic bacteria were similar in both groups. Nausea significantly diminished in both groups (p < 0.001) at the end of the trial. Furthermore, the symbiotic group had a statistically significant decrease in the frequency and intensity of vomiting when compared to the control group (p < 0.001). Conclusions: the symbiotic treatment decreases significantly the FCP levels and the frequency and intensity of vomiting in patients with CC


Introducción: los pacientes con cáncer cervical (CC) tratados con quimioterapia y radioterapia tienen frecuentemente efectos gastrointestinales adversos (EGA). Objetivo: evaluar el efecto de la suplementación dietética con simbióticos en la calprotectina fecal (FCP), el DNA bacteriano y sobre los EGA en pacientes con CC. Métodos: se realizó un ensayo clínico, aleatorizado y doble ciego. Los pacientes ingirieron simbióticos o placebo tres veces al día durante siete semanas. La FCP se evaluó mediante el método de ELISA. El ADN bacteriano se cuantificó mediante PCR en tiempo real. Las evacuaciones se evaluaron con la escala de Bristol y las náuseas y los vómitos se cuantificaron utilizando la escala del Instituto Nacional de Cancerología (USA). Resultados: después de siete semanas de tratamiento, la concentración de FCP fue menor en el grupo tratado con simbióticos en comparación al grupo control (p < 0,001). La consistencia de las heces en los grupos tratados con placebo y simbióticos fue similar al inicio del estudio. Se obtuvo una mejora significativa en la consistencia de las heces en ambos grupos al final de la intervención (p < 0,001). Los niveles de las bacterias probióticas y patogénicas fueron similares en ambos grupos. Los casos de náuseas disminuyeron en ambos grupos (p < 0,001) y el grupo tratado con simbióticos tuvo una disminución significativa en la frecuencia e intensidad de los vómitos en comparación al grupo control (p < 0,001). Conclusiones: el tratamiento simbiótico disminuye significativamente los niveles de FCP y la frecuencia e intensidad del vómito en pacientes con CC


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Fezes/química , Fezes/microbiologia , Complexo Antígeno L1 Leucocitário/análise , Prebióticos/administração & dosagem , Probióticos/administração & dosagem , Neoplasias do Colo do Útero/complicações , Neoplasias do Colo do Útero/terapia , Antineoplásicos/efeitos adversos , Bifidobacterium/genética , DNA Bacteriano/análise , Suplementos Nutricionais , Método Duplo-Cego , Escherichia coli/genética , Gastroenteropatias/etiologia , Gastroenteropatias/prevenção & controle , Inflamação/etiologia , Inflamação/prevenção & controle , Lactobacillales/genética , Placebos , Radioterapia/efeitos adversos , Salmonella/genética
3.
Rev. cuba. salud pública ; 39(1): 19-31, ene.-mar. 2013.
Artigo em Espanhol | LILACS | ID: lil-686814

RESUMO

Introducción: las intervenciones durante el tratamiento en el paciente oncológico, aumentan los riesgos para sufrir una infección nosocomial. En el Instituto Jalisciense de Cancerología, la prevención, identificación y seguimiento de las infecciones nosocomiales se realiza a través del programa de epidemiologia y por el Comité de Vigilancia Epidemiológica. Objetivos: determinar la incidencia de infecciones nosocomiales en pacientes oncológicos atendidos en el citado instituto. Métodos: se trata de un estudio descriptivo retrospectivo. Se tomaron en cuenta 5 056 egresos de abril de 2008 a diciembre de 2010, de los cuales 140 pacientes presentaron 178 infecciones nosocomiales. Resultados: la tasa global de infecciones por 100 egresos, fue variable (2008: 5,8; en 2009: 3,5 y en 2010: 2,2). La infección de herida quirúrgica se mantuvo con las tasas más altas (2,9; 1,5; 1,1). El germen más frecuentemente aislado fue Escherichia coli (55 %, 34 %, 20 %), el hongo más frecuente fue la Candida albicans (6 %, 7 %, 6 %). El promedio días estancia en el momento de la captación de la infección, fue de 3,3 días y en el momento del egreso fue de 17 días. La tasa de letalidad, fue de 19 por cada 100 casos, y la tasa de mortalidad 27 por cada 100 casos. Conclusiones: se observa una disminución en la tasa de infección nosocomial en los últimos años. La intervención del Servicio de Epidemiología con sus acciones dirigidas de manera específica, al manejo de las heridas quirúrgicas, es fundamental.


Background: the treatments in cancer patients increase the risk of catching nosocomial infection. In the Instituto Jalisciense de Cancerología, the prevention, identification and monitoring of nosocomial infections is carried out by the Epidemiological Surveillance Committee through an epidemiological program. Objectives: To determine the incidence of nosocomial infections in cancer patients seen at the Instituto Jalisciense de Cancerología Methods: A retrospective and descriptive study, which included 5056 patients discharged from April 2008 to December 2010, of whom 140 had nosocomial infections. Results: The overall rate of infections per 100 discharges was variable (5.8 in 2008; 3.5 in 2009 and 2.2 in 2010). The surgical wound infection kept the highest rates (2.9, 1.5, 1.1 respectively). The most common isolated bacteria was Escherichia coli (55 %, 34 %, 20 %); the most frequent fungus was Candida albicans (6 %, 7 %, 6 %). The average length of stay at the time of catching the infection was 3.3 days, and at the time of hospital discharge was 17 days. The fatality rate was 19 per 100 cases whereas the mortality rate was 27 per 100 cases. Conclusions: a decrease in the rate of nosocomial infection was observed in recent years; where the epidemiology service was the key to implementing epidemiological actions, in particular the management of surgical wounds.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...